

ACRUX AGM PRESENTATION (ASX: ACR)

OH

H3C

November 2018



INTRODUCTION:

ROSS DOBINSON NON-EXECUTIVE CHAIRMAN





OPERATIONAL REVIEW:

MICHAEL KOTSANIS CEO & MANAGING DIRECTOR





FORWARD LOOKING STATEMENTS

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.



STRONG OPERATIONAL AND COMMERCIAL PROGRESS



Deliberate expansion & optimisation of portfolio

 Successfully expanded generic topical portfolio from 7 to 13 products and conducted ground work to add further products to the pipeline in FY19



On-target regulatory submissions

 Demonstrated successful execution of strategy - achieving first and second submissions to the FDA (accepted for review in August and October 2018) and completion of a pharmacokinetic (PK) bioequivalence trial



Continued excellence in research & development

Significant progression and increase in R&D projects including market screening to identify high potential topical products and successful formulation development of multiple products



Consistent operational execution

 Successfully engaged additional Contract Manufacturing Organisations (CMO) that are FDA approved and during FY19 will begin to scale up 6 projects from laboratory to exhibit batch manufacturing



Attracted commercial interest

 Received commercial interest in the portfolio from several parties. Generic pharmaceutical companies place high value on generic portfolios



Increased investor engagement

- Market responded to catalysts (generic Jublia[®] and testosterone solution FDA dossiers), share price increased in response
- Increased activity in investor engagement with increasing generic milestones and events



INCREASING INVESTOR ENGAGEMENT



Key recent catalysts: 02 August: Acrux has aragraph IV generic of Jublia® accepted for review by FDA

Key recent catalysts: 17 October: Acrux has generic testosterone solution submission accepted for review by FDA


Cash backing per share of 17c (as at 30 June 2018)





Acrux is developing a diversified portfolio of <u>topically applied</u> <u>generic products</u>

OUR APPROACH





MULTIPLE ADVANTAGES FOR GENERIC PRESCRIPTION PRODUCT DEVELOPMENT

	Traditional development	Acrux's generic development portfolio
Market size	A new drug may have a significant market opportunity, however	Attractive market and licensee terms
Speed	it takes ~10 years¹ to develop a new drug, involving multiple expensive trials	Fast development and low cost
Risk	and typically less than 12% of drug candidates make it into Phase I clinical trials ¹	Lower risk than branded development



ACRUX IS MAKING EXCELLENT PROGRESS ACROSS ITS GENERIC TOPICAL PORTFOLIO

In FY19, Acrux intends to:

- Submit 1 additional dossier to the FDA for review, in addition to dossier recently submitted
- ✓ Scale up 6 projects from Acrux laboratory to CMOs¹
- Add additional products to the ACR generic topical portfolio



Acrux expects to generate first revenues from its generic portfolio in CY19


9

Overview of Acrux's current generic topical portfolio of 13 assets

		Formulation Development	Process Development	Bioequiv. / clinical ²	Regulatory Submission	Approved / Launched
Branded equivalent	Target area	Development phase		Commercialisation phase		
Jublia [®] To	enail Infection					
None	Testosterone				*	
Not yet c	disclosed					
Not yet c	disclosed					
Not yet c	disclosed					
Not yet c	disclosed					
Not yet c	disclosed					
Not yet c	disclosed					
Not yet c	disclosed					
Not yet c	: Not yet disclosed					
Not yet c	disclosed					
Not yet c	disclosed					
Not yet c	disclosed					
Legend	d: Pro	gress as at FY17	,	Progres	ss during FY18	



ACRUX PIPELINE REPRESENTS A LARGE MARKET WITH RELATIVELY LOW COMPETITION



Addressable market of portfolio as at June 2018




EACH DRUG IN ACRUX'S GENERIC TOPICAL PORTFOLIO WILL FOLLOW THE SAME COMMERCIALISATION PATHWAY

An illustrative pathway for a successfully launched asset:

Submit dossier to	Secure licensing	Launch product	Generate ongoing
FDA for filing	agreement		revenue stream
 Submit dossier for review FDA accepts the dossier for review within 60 days of submission 	 Seek to license the asset to a generic company who will market and sell the product in the US Double-digit royalties common for generic products 	 FDA target review period is less than 12 months. Where IP legal proceedings are initiated (expected for a subset of two products in the current portfolio), this may delay launch 	 Licencing arrangement creates a revenue stream for Acrux at zero cost Revenue can then be reinvested to further expand the pipeline



FIRST GENERIC TOPICAL PRODUCT TO REACH 'FDA REVIEW'






12



Topical generics represent an attractive and significant market opportunity

- ✓ US\$18bn market opportunity
- Currently, generics make up only 47% of the topical market, this is expected to grow
- Technical expertise required to develop and manufacture topicals as products can come in many different forms, increasing barriers to entry
- Acrux has established in-house development capabilities
- ✓ Generic manufacturers achieve excellent EBITDA margins (+25%)³

ACRUX IS OPERATING IN AN ATTRACTIVE US\$18bn MARKET



1. US market by dosage form, IQVIA Q2, 2015 MAT. US market sales (US\$)

2. Market size for topically applied drugs IQVIA Q3, 2017 MAT (US\$) 3. Citi Research – Generics Landscape Chart Pack (Jan 2017)



EXPERIENCED MANAGEMENT TEAM WITH A PROVEN HISTORY OF MEETING OPERATIONAL MILESTONES

Management team



Michael Kotsanis BSc, MBus CEO & Managing Director



Experienced leader in the pharmaceuticals industry with demonstrated success commercialising generic products



Felicia Colagrande, BSc(Hons), MBA

Product Development and Technical Affairs Director

+ Faulding

+ Faulding

Deep experience in pharmaceutical operations, dermal drug development, analytical development and production. Felicia leads and facilitates all technical aspects of pharmaceutical product development including R&D, analytical development, project management and CMC development



Charles O'Sullivan, B. Pharm Portfolio Director



Experienced healthcare executive with senior and international leadership roles in scientific affairs, medical affairs, health economics and government affairs. Previously Asia Pacific Director of Medical and Government Affairs for Hospira Inc (now Pfizer)



Tim Bateman CA CFO & Company Secretary



Extensive financial experience and senior finance role. Tim was the Group Chief Financial Officer at Vix Technology for 10 years where his responsibilities included financial management, corporate governance, supporting strategic planning, M&A activities and capital raising

World class topical R&D team

"I am extremely proud to lead an **expert topical drug development team**. Our inhouse skill set provides us with an **unique advantage**, supported by robust processes, competent regulatory acumen and our ability to **deliver products through development to commercialisation**."



Felicia Colagrande, Product Development and Technical Affairs Director



25 *researchers with experience in developing pharma products*

350+

years of combined experience in drug development

1 common goal: develop highvalue topical generics



STRATEGIC DIRECTION LED BY A BOARD WITH HIGHLY RELEVANT EXPERTISE



Michael Kotsanis CEO & Managing Director

sanis Synthen Hospira #Faulding maynepharma

- Experienced leader in the pharmaceuticals industry with demonstrated success commercialising generic products
- Michael was formally the Chief Commercial Officer for Synthon Holding BV, an international pharmaceutical company and a **leader in the field of generic medicines**
- Prior to Synthon Michael was President, Europe for Hospira Inc - the **largest global generic injectable company**



Ross Dobinson Non-Executive Chairman



Capital markets expert with a wealth of experience advising and establishing life science companies



Simon Green Non-Executive Director

- Extensive biotech drug development and commercial manufacturing experience
- Formerly senior vice president and general manager, CSL Ltd



Geoff Brooke Non-Executive Director

- Founded GBS Venture Partners
- Former president of Medvest Inc, a venture capital group he founded with Johnson & Johnson



- Former CEO of Cell Therapies Pty Ltd
- Former president of Asia Pacific for Hospira Inc and previously held a variety of senior management roles with Mayne Pharma Ltd



MULTIPLE UPCOMING VALUE CATALYSTS

generic portfolio in CY19

Acrux objectives				
	FY19			
Submit 2 additional dossiers to FDA	Scale up 6 project from Acrux laboratory to CMOs	s Add further products to generic portfolio		
CY19				
First ge	PUELIC	ux expects to generate frst revenues from its		

revenues







FINANCIAL REVIEW:

TIM BATEMAN CFO



FULL YEAR PROFIT AND LOSS

	Full Year Ending		
	2018	2017	
	\$'000	\$'000	%
Royalty revenue	2,687	23,321	(88.5%)
Interest & other Income	745	613	21.5%
Total revenue and other income	3,432	23,934	(85.7%)
R&D investment	(10,624)	(9,247)	14.9%
Other operating costs	(2,705)	(2,198)	23.1%
Non operating costs	(581)	(1,903)	(69.5%)
Total expenses	(13,910)	(13,348)	4.2%
Operating (loss)/profit before impairment loss and income tax	(10,478)	10,586	(199.0%)
Impairmentloss	(5,647)	(10,680)	-
Operating loss before income tax	(16,125)	(94)	17065.7%
Income tax benefit/(expense)	1,943	(149)	(1404.0%)
Net loss for the year	(14,182)	(243)	5737.8%
Loss per share			
Basic loss per share	(8.52) cents	(0.15) cents	(8.37) cents
Cash reserves	28,470	33,974	(16.2%)



FULL YEAR CASHFLOW

	Full Year Ending		
	2018 2017		
	\$'000	\$'000	%
Cash flow from operating activities			
Receipts from product agreements	7,872	21,822	(63.9%)
Payments to suppliers and employees	(12,731)	(10,748)	18.4%
Interest received	610	637	(4.2%)
Income tax paid	(1,033)	(6,335)	(83.7%)
Net cash (used in)/provided by operating activities	(5,282)	5,376	(198.3%)
Cash flow from investing activities			
Payment for property, plant and equipment	(296)	(629)	(52.9%)
Net cash used in investing activities	(296)	(629)	(52.9%)
Net (decrease)/increase in cash and cash equivalents	(5 <i>,</i> 578)	4,747	(217.5%)
Cash at beginning of year	33,974	29,360	15.7%
Foreign exchange differences on cash holdings	74	(133)	(155.6%)
Cash and at end of the year	28,470	33,974	(16.2%)



THANK YOU

Michael Kotsanis

Acrux Limited CEO & Managing Director P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

Visit our website: <u>http://www.acrux.com.au/</u> Follow us on LinkedIn:



Investor enquiries

Anthony England Vesparum Capital Director P: + 61 3 8582 4800 E: Acrux@vesparum.com